PHOENIX, AZ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)THE INTERNATIONAL GENOMICS CONSORTIUM, founded in 2001, is a micro nonprofit in the Medical Research sector that reported $84K in total revenue in fiscal year 2023. Revenue fell 71% from the prior year — a significant decline worth monitoring. Expenses of $1.4M exceeded revenue, resulting in a 1584% operating deficit.
THE MISSION OF IGC IS TO REVOLUTIONIZE THE TREATMENT AND PREVENTION OF CANCER AND COMPLEX DISEASES BY RIGOROUSLY DEVELOPING AND APPLYING POST-GENOME SCIENCE TO ADVANCES IN HUMAN HEALTH.
ISPECIMEN - ISPECIMEN ADDRESSES A CRITICAL CHALLENGE CONNECTING LIFE SCIENCE RESEARCHERS WHO NEED HUMAN BIOSPECIMENS WITH THE BILLIONS OF SPECIMENS AVAILABLE IN HEALTHCARE ORGANIZATIONS WORLDWIDE...
ISPECIMEN - ISPECIMEN ADDRESSES A CRITICAL CHALLENGE CONNECTING LIFE SCIENCE RESEARCHERS WHO NEED HUMAN BIOSPECIMENS WITH THE BILLIONS OF SPECIMENS AVAILABLE IN HEALTHCARE ORGANIZATIONS WORLDWIDE. ISPECIMEN'S GROUND-BREAKING MARKETPLACE SOLVES THIS PROBLEM, REINVENTING THE BIOSPECIMEN PROCUREMENT PROCESS TO ACCELERATE MEDICAL RECOVERY.IGC CONTINUES TO BUILD ON THEIR ONGOING RESEARCH COLLABORATIONS WITH A VARIETY OF HOSPITALS INCLUDING WITH SCOTTSDALE HEALTHCARE HOSPITAL (NOW HONORHEALTH) BY PROVIDING ACCESS TO ITS BANKED SPECIMENS WITH CLINICAL DATA GATHERED IN COLLABORATION WITH THE HEALTH CARE CENTERS WHICH ARE REDISTRIBUTED TO SUPPORT A VARIETY OF RESEARCH INCLUDING THE CANCER GENOME ATLAS PROJECT AT THE NATIONAL CANCER INSTITUTE AND FOLLOW ON STUDIES AND DATA ACCESS QUERIES. ADDITIONALLY, IGC LEVERAGES THE SPECIMENS AND DATA COLLECTED FROM THEIR HOSPITAL AND CLINICAL COLLABORATORS TO ACCELERATE AND INCUBATE INNOVATIVE RESEARCH PROGRAMS IN WOMEN'S HEALTH, EARLY CANCER DIAGNOSTICS AND TO FIND NEW PATHWAYS FOR INNOVATIVE TREATMENT METHODS.PARADIGM DIAGNOSTICS - PARADIGM'S RESEARCH BRINGS CUTTING EDGE DIAGNOSTICS AND BIOMARKER DRIVEN CLINICAL TRIALS TO THE BENEFIT OF CANCER PATIENTS. PARADIGM ATTEMPTS TO DEVELOP POTENTIAL THERAPIES BASED ON SPECIFIC CHARACTERIZATION OF THE PATIENT'S TUMOR, PERSONALIZING EACH PATIENT'S COURSE OF TREATMENT.
VIOMICS - DIAGNOSTIC AND BIOMARKER RESEARCH WITH A FOCUS ON LUNG CANCER.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2023 | 2022 | Change | |
|---|---|---|---|
| Revenue | $83,902 | $294,190 | -0.7% |
| Expenses | $1,413,171 | $1,516,541 | -0.1% |
| Net Income | $-1,329,269 | $-1,222,351 | +0.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DAVID MALLERY | CEO | 32.00 |
Officer
Director
|
$600,000 | $63,981 | $663,981 |
| TROY SHELTON | BOARD MEMBER | 0.50 |
Director
|
$3,000 | $0 | $3,000 |
| SCOTT MORRIS | CSO | 24.00 |
Officer
|
$141,158 | $36,451 | $177,609 |
| VANESA ROMERO | CFO | 16.00 |
Officer
|
$40,404 | $30,405 | $70,809 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | No data | No data | No data | No data |
| 2023 | $83,902 | $1,413,171 | $10,812,620 | $-1,329,269 |
| 2022 | $294,190 | $1,516,541 | $10,251,570 | $-1,222,351 |
| 2021 | $3,350,681 | $2,004,244 | $13,871,737 | $1,346,437 |
| 2020 | $14,905,841 | $1,983,807 | $18,148,841 | $12,922,034 |
| 2019 | $2,383,718 | $1,555,280 | $4,615,825 | $828,438 |
| 2018 | $2,449,951 | $1,426,782 | $4,286,362 | $1,023,169 |
Compare THE INTERNATIONAL GENOMICS CONSORTIUM with other nonprofits in Arizona and across the country.